title: Pulmonary disposition of vancomycin nebulized as lipid vesicles in rats.
abstract: Formulation of antibiotics as inhalable products is proposed to improve their therapeutic index when intended for the treatment of pulmonary infections; as vancomycin shows reduced values of lung partition coefficient, pulmonary administration might be an interesting alternative to conventional administration routes. An experimental study has been performed to compare the pulmonary disposition of vancomycin after inhalation of the drug formulated as a solution and as lipid vesicles (conventional liposomes or liposomes modified with chitosan). Vancomycin concentrations were determined in bronchoalveolar fluid, pulmonary tissue and blood samples from 27 Wistar rats distributed in three groups subjected to nebulisation of the drug formulated as a solution, conventional liposomes or chitosomes. Statistically significant differences between the mean drug concentrations in bronchoalveolar lavage (BALF) and lung tissue were found upon comparing the solution to lipid vesicles (116.95 μg ml(-1)±62.13 versus 68.34 μg ml(-1)±28.90 for liposomes and 65.36±22.11 μg g(-1) for chitosomes in BALF; 222.74±37.15 μg g(-1) versus 357.17±65.37 μg g(-1) for liposomes and 378.83±85.87 μg g(-1) for chitosomes in pulmonary tissue). The amount of available drug estimated by mass balance reached the highest values for chitosomes followed by liposomes (24289.66±4795.48 μg and 20207.91±5318.29 μg, respectively) and the lowest for the solution (18971.64±4765.38 μg). The drug transport and tissue uptake processes showed to be dependent on the nebulized formulation, being facilitated by the lipid vesicles that improved drug passage from the airway space to the pulmonary tissue and systemic circulation.
authors.affiliation: Department of Pharmacy, University of Salamanca, Salamanca, Spain.
authors.forename: M J
authors.initials: MJ
authors.lastname: de Jesús Valle
authors.forename: J Garavís
authors.initials: JG
authors.lastname: González
authors.forename: F González
authors.initials: FG
authors.lastname: López
authors.forename: A Sánchez
authors.initials: AS
authors.lastname: Navarro
mesh_terms: D000280:Administration, Inhalation; D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000493:pharmacokinetics*; D001692:Biological Transport; D001992:Bronchoalveolar Lavage Fluid / Q000737:chemistry; D048271:Chitosan / Q000737:chemistry*; D016503:Drug Delivery Systems; D008081:Liposomes; D008168:Lung / Q000378:metabolism*; D008297:Male; D009330:Nebulizers and Vaporizers; D051381:Rats; D017208:Rats, Wistar; D014018:Tissue Distribution; D014640:Vancomycin / Q000008:administration & dosage / Q000493:pharmacokinetics*
chemical_list: D000900:Anti-Bacterial Agents; D008081:Liposomes; D014640:Vancomycin; D048271:Chitosan